Vitamin D, smoking, EBV, and long-term cognitive performance in MS
暂无分享,去创建一个
X. Montalban | L. Kappos | H. Hartung | M. Freedman | B. Hemmer | G. Edan | F. Foley | I. Penner | S. Schippling | J. Kuhle | C. Barro | A. Ascherio | E. H. Martinez-Lapiscina | K. Munger | E. Wicklein | E. Fox | Marianna Cortese | E. Martinez-Lapiscina
[1] K. Blennow,et al. Vitamin D supplementation and neurofilament light chain in multiple sclerosis , 2018, Acta neurologica Scandinavica.
[2] C. McCulloch,et al. Body mass index, but not vitamin D status, is associated with brain volume change in MS , 2018, Neurology.
[3] D. Langdon,et al. How does cognition relate to employment in multiple sclerosis? A systematic review. , 2018, Multiple sclerosis and related disorders.
[4] Massimo Filippi,et al. Cognition in multiple sclerosis , 2018, Neurology.
[5] J. DeLuca,et al. Evidenced-Based Cognitive Rehabilitation for Persons With Multiple Sclerosis: An Updated Review of the Literature From 2007 to 2016. , 2017, Archives of physical medicine and rehabilitation.
[6] C. Russo,et al. The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests , 2017, Multiple sclerosis.
[7] Ludwig Kappos,et al. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis , 2017, Annals of neurology.
[8] S. Khoury,et al. Effect of Vitamin D Replacement on Cognition in Multiple Sclerosis Patients , 2017, Scientific Reports.
[9] Sungroul Kim. Overview of Cotinine Cutoff Values for Smoking Status Classification , 2016, International journal of environmental research and public health.
[10] J. Damoiseaux,et al. Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNβ; the SOLARIUM study , 2016, Journal of Neuroimmunology.
[11] Henrik Zetterberg,et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa , 2016, Clinical chemistry and laboratory medicine.
[12] F. Barkhof,et al. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial , 2016, Neurology.
[13] T. Holmøy,et al. No association of tobacco use and disease activity in multiple sclerosis , 2016, Neurology: Neuroimmunology & Neuroinflammation.
[14] A. Ascherio,et al. Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention—An Update , 2016, Seminars in Neurology.
[15] R. Benedict,et al. Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis , 2016, CNS Drugs.
[16] M. Ramanathan,et al. Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS , 2016, Neurology: Neuroimmunology & Neuroinflammation.
[17] D. Goodin,et al. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. , 2015, JAMA neurology.
[18] David H. Miller,et al. No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT , 2015, Neurology.
[19] H. Karadeli,et al. Association between smoking and cognitive impairment in multiple sclerosis , 2014, Neuropsychiatric disease and treatment.
[20] Ludwig Kappos,et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. , 2014, JAMA neurology.
[21] G. Ketels,et al. Effects of exercise on fitness and cognition in progressive MS: a randomized, controlled pilot trial , 2014, Multiple sclerosis.
[22] J. Salzer,et al. Vitamin D and multiple sclerosis: where do we go from here? , 2014, Expert review of neurotherapeutics.
[23] C. Tench,et al. Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study , 2013, Brain : a journal of neurology.
[24] M. Ramanathan,et al. Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study , 2013, PloS one.
[25] M. Calabrese,et al. Cortical lesion load associates with progression of disability in multiple sclerosis. , 2012, Brain : a journal of neurology.
[26] C. McCulloch,et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis , 2012, Annals of neurology.
[27] David H. Miller,et al. Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis , 2012, Multiple sclerosis.
[28] R. Benedict,et al. Risk factors for and management of cognitive dysfunction in multiple sclerosis , 2011, Nature Reviews Neurology.
[29] Z. Fedorowicz,et al. Vitamin D for the management of multiple sclerosis. , 2010, The Cochrane database of systematic reviews.
[30] G. Ingram,et al. Anti‐EBNA‐1 IgG is not a reliable marker of multiple sclerosis clinical disease activity , 2010, European journal of neurology.
[31] Timothy C. Durazzo,et al. Chronic Cigarette Smoking: Implications for Neurocognition and Brain Neurobiology , 2010, International journal of environmental research and public health.
[32] T. Dwyer,et al. Higher 25‐hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis , 2010, Annals of neurology.
[33] J. Lünemann,et al. Elevated Epstein–Barr virus‐encoded nuclear antigen‐1 immune responses predict conversion to multiple sclerosis , 2010, Annals of neurology.
[34] G. Wylie,et al. Intellectual enrichment is linked to cerebral efficiency in multiple sclerosis: functional magnetic resonance imaging evidence for cognitive reserve , 2009, Brain : a journal of neurology.
[35] L. Kappos,et al. The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue , 2009, Multiple sclerosis.
[36] N. Staff,et al. Multiple sclerosis with predominant, severe cognitive impairment. , 2009, Archives of neurology.
[37] M. Ramanathan,et al. Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis , 2009, Neurology.
[38] K. Schmierer,et al. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI , 2009, Neurology.
[39] Eman N. Ali,et al. Smoking and disease progression in multiple sclerosis. , 2009, Archives of neurology.
[40] L. Nyström,et al. Smoking worsens the prognosis in multiple sclerosis , 2008, Multiple sclerosis.
[41] J. De Keyser,et al. Cigarette smoking and progression in multiple sclerosis , 2007, Neurology.
[42] J. Erälinna,et al. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.
[43] A. Ascherio,et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. , 2006, JAMA.
[44] M. Hernán,et al. Cigarette smoking and the progression of multiple sclerosis. , 2005, Brain : a journal of neurology.
[45] S. Kishiyama,et al. Randomized controlled trial of yoga and exercise in multiple sclerosis , 2004, Neurology.
[46] Rohit Bakshi,et al. Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. , 2004, Archives of neurology.
[47] Y. Truong,et al. Cotinine concentrations in semen, urine, and blood of smokers and nonsmokers. , 1993, American journal of public health.
[48] S. Rao,et al. Cognitive dysfunction in multiple sclerosis. , 1991, Neurology.
[49] Stephen M. Rao,et al. Cognitive dysfunction in multiple sclerosis. , 1991, Neurology.
[50] M. Weissman,et al. Assessing depressive symptoms in five psychiatric populations: a validation study. , 1977, American journal of epidemiology.
[51] W. L. Benedict,et al. Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.